231 related articles for article (PubMed ID: 21033767)
1. Optimizing therapeutic antibody function: progress with Fc domain engineering.
Kaneko E; Niwa R
BioDrugs; 2011 Feb; 25(1):1-11. PubMed ID: 21033767
[TBL] [Abstract][Full Text] [Related]
2. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
3. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
7. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
Kelley RF; Meng YG
Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108
[TBL] [Abstract][Full Text] [Related]
8. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Johnson S; Koenig S; Bonvini E
Adv Enzyme Regul; 2008; 48():152-64. PubMed ID: 18177741
[No Abstract] [Full Text] [Related]
10. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
11. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
12. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
13. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
14. Engineered antibody Fc variants with enhanced effector function.
Lazar GA; Dang W; Karki S; Vafa O; Peng JS; Hyun L; Chan C; Chung HS; Eivazi A; Yoder SC; Vielmetter J; Carmichael DF; Hayes RJ; Dahiyat BI
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4005-10. PubMed ID: 16537476
[TBL] [Abstract][Full Text] [Related]
15. Selection, design, and engineering of therapeutic antibodies.
Presta LG
J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
[TBL] [Abstract][Full Text] [Related]
16. Engineered Fc-glycosylation switch to eliminate antibody effector function.
Zhou Q; Jaworski J; Zhou Y; Valente D; Cotton J; Honey D; Boudanova E; Beninga J; Rao E; Wei R; Mauriac C; Pan C; Park A; Qiu H
MAbs; 2020; 12(1):1814583. PubMed ID: 32892677
[TBL] [Abstract][Full Text] [Related]
17. Engineering therapeutic monoclonal antibodies.
Liu XY; Pop LM; Vitetta ES
Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
[TBL] [Abstract][Full Text] [Related]
18. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.
Fonseca MHG; Furtado GP; Bezerra MRL; Pontes LQ; Fernandes CFC
Int J Biol Macromol; 2018 Nov; 119():306-311. PubMed ID: 30041038
[TBL] [Abstract][Full Text] [Related]
19. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
[TBL] [Abstract][Full Text] [Related]
20. Harnessing Fc receptor biology in the design of therapeutic antibodies.
Sondermann P; Szymkowski DE
Curr Opin Immunol; 2016 Jun; 40():78-87. PubMed ID: 27038127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
